SCHEDULE OF NON CONTROLLING INTEREST (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Net loss attributable to the non-controlling interest	$ (32,894)	$ (51,116)
Subsidiaries [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Net loss Subsidiary	(139,004)		$ (817,151)
Net loss attributable to the non-controlling interest	32,894		193,372
Net loss affecting Bioxytran	(106,110)		(623,780)
Accumulated losses	(3,733,291)		(3,594,287)
Accumulated losses attributable to the non-controlling interest	784,472		751,578
Accumulated losses Bioxytran	(2,948,819)		(2,842,709)
Net equity non-controlling interest	$ (623,522)		$ (590,628)